Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Shares of Hims and Hers Health (NYSE:HIMS) slid 14% in premarket trading following the telehealth company’s announcement of ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ...

Hims shares fell $22.24, or over 34%, after Novo’s announcement, declining from $64.22 per share on June 20 to close at $41.98 per share on June 23. The stock closed on Monday at $52.03 a share.

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.

Business Economy Health Technology Hims & Hers’ ugly split with Wegovy maker weighs on the firm’s future July 7, 2025 at 6:00 am Updated July 7, 2025 at 6:00 am By Queenie Wong ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...